USE OF LORAZEPAM FOR PEDIATRIC STATUS EPILEPTICUS (COHORT 2)

这个子项目是众多研究子项目之一

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the multi-center study is to look at the pharmacokinetics of lorazepam for the treatment of pediatric status epileticus. The study has two cohorts. Cohort 1 is for patients that can be enrolled/dosed while actively seizing and cohort 2 is for patients that will be electively enrolled/dosed. The exclusion criterion for cohort 2 has been changed to excluded patients if they have unexplained renal or hepatic disease greater that twice the limit than normal or 2-fold increase of the patients baseline value. The sample size has been adjusted from 60 to 100 patients and the study has been extended until May 1, 2006.